Clinical guidance on the contemporary use of proprotein convertase subtilisin/kexin type 9 monoclonal antibodies

Research output: Contribution to journalArticle

Abstract

There is now significant evidence for the benefits of lowering low-density lipoprotein cholesterol (LDL-c) to reduce the risk of atherosclerotic cardiovascular disease (ASCVD). Although statins are the most widely prescribed lipid-lowering therapy that effectively lower LDL-c, especially in combination with ezetimibe, some patients require adjunctive therapy to further lower LDL-c and mitigate attendant risk of ASCVD. The gap can be filled by proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies whose use is currently supported by two recent cardiovascular outcome studies and new treatment guidelines. We provide an overview of extant studies investigating PCSK9 monoclonal antibodies in various patient populations, an update of the guidelines regarding their use and a case-based discussion.

Original languageEnglish
Pages (from-to)52-62
Number of pages11
JournalDiabetes, Obesity and Metabolism
Volume21
Issue numberS1
DOIs
Publication statusPublished - 1 Apr 2019

Fingerprint

LDL Cholesterol
Monoclonal Antibodies
Cardiovascular Diseases
Guidelines
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Therapeutics
Outcome Assessment (Health Care)
Lipids
Population
Proprotein Convertase 9
Ezetimibe

Cite this

@article{79c9b007d8f54be7b449e8cec380873e,
title = "Clinical guidance on the contemporary use of proprotein convertase subtilisin/kexin type 9 monoclonal antibodies",
abstract = "There is now significant evidence for the benefits of lowering low-density lipoprotein cholesterol (LDL-c) to reduce the risk of atherosclerotic cardiovascular disease (ASCVD). Although statins are the most widely prescribed lipid-lowering therapy that effectively lower LDL-c, especially in combination with ezetimibe, some patients require adjunctive therapy to further lower LDL-c and mitigate attendant risk of ASCVD. The gap can be filled by proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies whose use is currently supported by two recent cardiovascular outcome studies and new treatment guidelines. We provide an overview of extant studies investigating PCSK9 monoclonal antibodies in various patient populations, an update of the guidelines regarding their use and a case-based discussion.",
keywords = "cardiovascular disease, lipid-lowering therapy, type 2 diabetes",
author = "Ward, {Natalie C.} and Page, {Michael M.} and Watts, {Gerald F.}",
year = "2019",
month = "4",
day = "1",
doi = "10.1111/dom.13637",
language = "English",
volume = "21",
pages = "52--62",
journal = "Diabets, Obesity and Metabolism",
issn = "1462-8902",
publisher = "Wiley-Blackwell",
number = "S1",

}

TY - JOUR

T1 - Clinical guidance on the contemporary use of proprotein convertase subtilisin/kexin type 9 monoclonal antibodies

AU - Ward, Natalie C.

AU - Page, Michael M.

AU - Watts, Gerald F.

PY - 2019/4/1

Y1 - 2019/4/1

N2 - There is now significant evidence for the benefits of lowering low-density lipoprotein cholesterol (LDL-c) to reduce the risk of atherosclerotic cardiovascular disease (ASCVD). Although statins are the most widely prescribed lipid-lowering therapy that effectively lower LDL-c, especially in combination with ezetimibe, some patients require adjunctive therapy to further lower LDL-c and mitigate attendant risk of ASCVD. The gap can be filled by proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies whose use is currently supported by two recent cardiovascular outcome studies and new treatment guidelines. We provide an overview of extant studies investigating PCSK9 monoclonal antibodies in various patient populations, an update of the guidelines regarding their use and a case-based discussion.

AB - There is now significant evidence for the benefits of lowering low-density lipoprotein cholesterol (LDL-c) to reduce the risk of atherosclerotic cardiovascular disease (ASCVD). Although statins are the most widely prescribed lipid-lowering therapy that effectively lower LDL-c, especially in combination with ezetimibe, some patients require adjunctive therapy to further lower LDL-c and mitigate attendant risk of ASCVD. The gap can be filled by proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies whose use is currently supported by two recent cardiovascular outcome studies and new treatment guidelines. We provide an overview of extant studies investigating PCSK9 monoclonal antibodies in various patient populations, an update of the guidelines regarding their use and a case-based discussion.

KW - cardiovascular disease

KW - lipid-lowering therapy

KW - type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=85064623970&partnerID=8YFLogxK

U2 - 10.1111/dom.13637

DO - 10.1111/dom.13637

M3 - Article

VL - 21

SP - 52

EP - 62

JO - Diabets, Obesity and Metabolism

JF - Diabets, Obesity and Metabolism

SN - 1462-8902

IS - S1

ER -